
    
      This study is a Phase II, randomized, parallel-group, active-controlled, double-blind, dose
      ranging, multicenter study with 4 different doses of Creon IR and one dose of the active
      control CreonÂ® (DR/GR), administered in subjects of 12 years or older with PEI due to CF.

      The study is divided into two periods: a screening period of 14 days and a double-blind
      treatment period of 6 to 7 days.
    
  